Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • Guaranteed Paid Placement
  • SocialBoost
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • SocialBoost
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

From Refugee to Philanthropist, New Memoir Chronicles Journey of Jan Vilcek

"Love and Science" shares a remarkably American story, from escaping communism to changing millions of lives with a blockbuster drug


News provided by

The Vilcek Foundation

Feb 09, 2016, 09:30 ET

Share this article

Share toX

Share this article

Share toX

From refugee to philanthropist, "Love and Science" chronicles the journey of immunologist Jan Vilcek. Published by Seven Stories Press, the memoir details how he defected from communist Czechoslovakia, after surviving World War II in hiding, and immigrated to the U.S. with his wife, Marica, as penniless political refugees. In New York, Dr. Vilcek's research led to the development of Remicade, a revolutionary new treatment for autoimmune and inflammatory diseases. "Love and Science" is an inspiring story of hardships and accomplishments, both personal and professional, and proof of the importance of immigrant contributions to American society.
From refugee to philanthropist, "Love and Science" chronicles the journey of immunologist Jan Vilcek. Published by Seven Stories Press, the memoir details how he defected from communist Czechoslovakia, after surviving World War II in hiding, and immigrated to the U.S. with his wife, Marica, as penniless political refugees. In New York, Dr. Vilcek's research led to the development of Remicade, a revolutionary new treatment for autoimmune and inflammatory diseases. "Love and Science" is an inspiring story of hardships and accomplishments, both personal and professional, and proof of the importance of immigrant contributions to American society.

NEW YORK, Feb. 9, 2016 /PRNewswire-USNewswire/ -- The life of Dr. Jan Vilcek, celebrated immunologist at NYU Langone Medical Center, has been anything but ordinary.  Twists of fate, combined with sheer grit, brought him from the devastation of World War II and the constraints of communist Czechoslovakia to New York City in the 1960s; there, he would go on to make history by playing a key role in the development of one of the three best-selling drugs in the world, Remicade.  Dr. Vilcek brings readers along his improbable journey in his new memoir, Love and Science (Seven Stories Press; 2/9/16).

Dr. Vilcek's story begins in the former Czechoslovakia, where, as a Jewish child World War II, he survived the constant, harrowing threat of deportation to an extermination camp, first hiding in a Catholic orphanage before later fleeing to the countryside.  Afterward, during the political turmoil caused by communist takeover, he completed medical school in Bratislava and embarked on a career in virology and immunology, two nascent fields whose importance were, at the time, unfathomable.

Frustrated by the lack of personal freedom, Dr. Vilcek and his wife, Marica, defected while on a weekend trip to Vienna and eventually immigrated to the U.S. in 1965.  Although the couple arrived as penniless refugees, NYU School of Medicine offered Dr. Vilcek a faculty position, while Marica, an art historian, found a professional home at the Metropolitan Museum of Art.  Dr. Vilcek went on to spearhead some of the key advances in the research of interferon and tumor necrosis factor (TNF), eventually leading to the development of Remicade, the first of a groundbreaking new class of medical treatments. 

One of the highest-grossing drugs in the world today, Remicade helps millions with crippling autoimmune and inflammatory diseases such as Crohn's and rheumatoid arthritis.  As a result of this success, Dr. Vilcek has become one of the major donors to NYU Langone Medical Center, where he continues to serve as a research professor in the department of microbiology.  Separately, the couple founded the Vilcek Foundation, which raises awareness of immigrant contributions to American society and fosters appreciation for the arts and sciences.  In 2013, President Obama awarded Dr. Vilcek one of America's top scientific honors: the National Medal of Technology and Innovation. 

Love and Science is an inspiring story of hardships and accomplishments, both personal and professional, and proof of the importance of immigrant contributions to the worlds of science and medicine.

About Dr. Jan T. Vilcek

Dr. Vilcek is a research professor in the department of microbiology at NYU Langone Medical Center.  Born in Bratislava, Slovakia (then Czechoslovakia), he immigrated, along with his wife, art historian Marica Vilcek, to the U.S. in 1965.  He is among the earliest researchers of interferon, an important immune system protein.  Dr. Vilcek's contributions to the understanding of proteins that control the body's defenses were instrumental in the development of the anti-inflammatory drug Remicade, the first member of a new class of therapeutics called TNF blockers.  Remicade, along with other TNF blockers, is now widely used for the treatment of Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis, and other chronic inflammatory disorders.  Dr. Vilcek has published more than 350 scholarly papers and written and edited several professional books.

The Vilcek Foundation was established in 2000 by Jan and Marica Vilcek, immigrants from the former Czechoslovakia.  The mission of the foundation, to honor the contributions of immigrants to the United States and to foster appreciation of the arts and sciences, was inspired by the couple's respective careers in biomedical science and art history, as well as their personal experiences and appreciation for the opportunities they received as newcomers to this country.  The foundation awards annual prizes to prominent immigrant biomedical scientists and artists, and sponsors cultural programs.

To learn more about the Vilcek Foundation, please visit Vilcek.org.

Photo - http://photos.prnewswire.com/prnh/20160208/330894

SOURCE The Vilcek Foundation

Related Links

http://www.vilcek.org

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

Vilcek Foundation Exhibition Features Monumental Works in Ballpoint Pen by Immigrant Artist Il Lee

Vilcek Foundation Exhibition Features Monumental Works in Ballpoint Pen by Immigrant Artist Il Lee

The Vilcek Foundation is proud to present their latest exhibition Il Lee—Energy and Flow: Abstraction of Movements, which features twenty-six works...

A Return to New Mexico--Tracing the Artistic Journey of Marsden Hartley

A Return to New Mexico--Tracing the Artistic Journey of Marsden Hartley

A robust collection of paintings, drawings, and belongings of prominent artist Marsden Hartley are now on display at the New Mexico Museum of Art in...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Biotechnology

Biotechnology

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.